Allergan’s Canadian Uterine Fibroid Registry Yields Better Understanding of Condition

A patent registry launched by Allergan with the aim of collecting observational data from Canadian women diagnosed with uterine fibroids is reportedly the first of its kind to compile this kind of real-world data. The CAPTURE registry includes information from more than 1,100 symptomatic patients, and could eventually help improve management of this condition.

“CAPTURE provides real-world evidence of the burden that Canadian women with symptomatic uterine fibroids experience, but also helps us better understand how we can improve the treatment of this debilitating condition,” said Dr. Nicholas Leyland, Chief of the Department of Obstetrics and Gynaecology at McMaster University. “We now have more than 1,100 patients registered in CAPTURE, meaning we’ll have a robust repository of data that will greatly benefit clinicians and patients in Canada, as well as around the world.”

Early findings from the CAPTURE dataset indicate that patients with symptomatic uterine fibroids experience symptoms such as heavy menstrual bleeding and pain which contribute to a poor quality of life. Allergan presented their initial findings from the registry data at CanSAGE, the Annual Conference of the Canadian Society for the Advancement of Gynecologic Excellence.

According to the Canadian Medical Association, approximately 70 percent of women will develop uterine fibroids by the time they turn 50. Furthermore, 20 to 50 percent of these cases are symptomatic, making uterine fibroids the most common type of non-cancerous tumor in women during their reproductive years.

Historically, uterine fibroids have been treated through a hysterectomy in which all uterine tissue is removed. Since this surgical treatment option is not right for all patients, its important that physicians better understand patient needs for alternatives through registries like CAPTURE.

“The CAPTURE registry is already producing learnings that will help clinicians provide the best care to women with fibroids,” said Dr. Sony S. Singh, Associate Professor and Vice Chair of Gynaecology at The Ottawa Hospital and University of Ottawa. “For example, early analysis of data reveal patients’ desire to better understand non-surgical treatment options with half indicating they do not want a hysterectomy.”

In 2016, Allergan’s drug Fibristal was approved to treat uterine fibroids. Allergan plans to continue the CAPTURE program until 2019, though the registry may be open to patients after that date.